Research Article
Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly—A Subgroup Analysis of Routine Clinical Practice Data
Table 2
Analgesic medication immediately prior to treatment with tapentadol PR.
| | Aged >65 years (n = 752) | Aged ≤65 years (n = 282) |
| | Strong opioidsa | 353 (46.9%) | 113 (40.1%) | | Fentanyl (transdermal) | 129 (17.2%) | 36 (12.8%) | | Oxycodone/naloxone | 74 (9.8%) | 30 (10.6%) | | Oxycodone | 61 (8.1%) | 26 (9.2%) | | Buprenorphine | 56 (7.5%) | 9 (3.2%) | | Morphine | 37 (4.9%) | 19 (6.7%) | | Hydromorphone | 33 (4.4%) | 9 (3.2%) | | Other | 1 (0.1%) | 1 (0.4%) | | Weak opioidsa | 396 (52.7%) | 166 (58.9%) | | Tramadol | 214 (28.5%) | 100 (35.5%) | | Tilidine/naloxone | 200 (26.6%) | 76 (27%) | | Other/not specified | 1 (0.1%) | 0 | | Nonopioidsa | 641 (85.2%) | 247 (87.6%) | | Nonsteroidal anti-inflammatory drugs | 468 (62.2%) | 199 (70.6%) | | Metamizole | 330 (43.9%) | 105 (37.2%) | | Muscle relaxants | 115 (15.3%) | 64 (22.7%) | | Paracetamol | 62 (8.2%) | 34 (12.1%) | | Other/not specified | 34 (4.5%) | 9 (3.2%) |
|
|
Data are number of patients (%); amultiple responses permitted. PR, prolonged release.
|
